TAMs are not a single, uniform cell type. They occupy a spectrum of functional states shaped by cytokines, metabolites, oxygen levels, acidity, mechanical forces and signals released by cancer and stromal cells. At one end are M1-like macrophages, which respond to inflammatory cues such as interferon-γ and tumor necrosis factor-α. Through pathways including JAK–STAT1, NF-κB and IRF5, these cells increase production of inflammatory mediators, nitric oxide and antigen-presentation machinery. They can help recruit CD8-positive cytotoxic T cells and natural killer cells. At the other end are M2-like programs, promoted by interleukins 4, 10 and 13, transforming growth factor-β and colony-stimulating factor 1. Signaling through STAT3, STAT6, PPARγ and PI3K–AKT–mTOR drives tissue repair, blood-vessel growth and immune suppression. In real tumors, macrophages rarely fit neatly into either category, but the M1/M2 framework remains useful for describing opposing immune functions.

The cancer-promoting side of this plasticity is extensive. M2-like TAMs can release epidermal growth factor, transforming growth factor-β and platelet-derived growth factor, supporting tumor-cell survival and proliferation. They produce matrix metalloproteinases and cathepsins that break down collagen and basement membranes, opening routes for invasion. They also secrete vascular endothelial growth factor, basic fibroblast growth factor and interleukin-8, encouraging the formation of abnormal blood vessels that feed the tumor and provide escape routes for metastasizing cells. Meanwhile, interleukin-10, transforming growth factor-β, PD-L1 and other suppressive signals blunt cytotoxic T cells and natural killer cells while attracting regulatory T cells and myeloid-derived suppressor cells. TAMs can even help maintain cancer stem-cell niches and interact with nerves, creating feedback loops that reinforce malignancy. Reprogramming them could therefore remodel immunity, blood vessels, extracellular matrix and tumor metabolism at the same time.

That possibility is especially attractive because tumors are difficult places for conventional drugs to reach. Dense stromal tissue, abnormal vasculature, low oxygen, acidic pH and high interstitial pressure can prevent therapeutic molecules from distributing evenly. Systemic cytokines, gene therapies and macrophage-directed drugs may also affect healthy tissues or lose effectiveness as tumors adapt. Physical stimulation offers a different mode of access: energy can be focused or applied repeatedly, with variables such as intensity, frequency, wavelength, pulse duration and temperature adjusted to the target. The review describes this as a controllable interface between engineering and immunology. Mechanical stress may open ion channels; light can excite sensitizers or alter redox chemistry; electric fields can change membrane permeability; magnetic particles can generate heat or release iron; and radiation can provoke immunogenic cell death. These inputs ultimately converge on the same inflammatory networks that govern macrophage behavior.

Light-based therapies illustrate both the promise and the engineering challenge. Photodynamic therapy activates a photosensitizer to generate reactive oxygen species, damaging tumor cells and inducing immunogenic cell death. That process can expose calreticulin, release ATP and liberate HMGB1, danger signals that alert dendritic cells and macrophages. Conventional type II photodynamic therapy depends heavily on molecular oxygen, making it vulnerable to the severe hypoxia found in solid tumors. Newer type I systems generate radicals such as superoxide and hydroxyl radicals under oxygen-poor conditions, while some nanoplatforms produce oxygen from hydrogen peroxide in the tumor. Type III photosensitizers aim to work without oxygen by transferring excitation energy directly to biomolecules such as RNA. Photothermal therapy takes another route, converting near-infrared light into heat. High temperatures can rapidly ablate tissue but risk collateral damage; mild heating around 42–45°C may instead improve perfusion, relieve hypoxia and activate NF-κB and STAT1-linked inflammatory programs. The trade-off is that heat-shock proteins can protect tumor cells, prompting efforts to inhibit HSP70 during treatment.

Ultrasound may be particularly useful for tumors buried deep within the body because acoustic energy can penetrate tissue and be focused under imaging guidance. High-intensity focused ultrasound can destroy tumor tissue through heat, releasing tumor antigens and heat-shock proteins that stimulate adaptive immunity. Mechanical forms of focused ultrasound, including histotripsy, use pressure waves and cavitation—the formation and collapse of microscopic bubbles—to fragment tissue while limiting thermal buildup. The resulting release of calreticulin and HMGB1 can push macrophages toward inflammatory activity. Yet the immune effect depends on the amount of tissue disrupted: very small ablation volumes may not provide enough antigenic material to overcome suppression, making combination with immune checkpoint blockade important. Ultrasound-targeted microbubble destruction offers a different mechanism. Cavitating microbubbles temporarily disturb blood-vessel walls and cell membranes, increasing vascular permeability and potentially altering macrophage recruitment. Sonodynamic therapy uses ultrasound to activate sensitizers and generate reactive oxygen species, pairing deep-tissue access with oxidative tumor injury. Its major obstacle remains hypoxia, which has spurred the development of oxygen-generating particles and systems that consume tumor lactate.

Electrical stimulation connects tumor treatment to the electrophysiology of immune cells. Nanosecond pulsed stimulation delivers extremely brief, intense electric pulses that create transient nanopores in cell and organelle membranes. The resulting calcium flux, endoplasmic-reticulum stress and reactive oxygen production can induce immunogenic cell death and activate inflammatory circuits such as cGAS–STING. Preclinical studies described in the review associate this approach with depletion of M2-like macrophages, increased M1-like activity and reductions in regulatory T cells and suppressor cells. Tumor-treating fields use much gentler alternating fields—roughly 1–3 volts per centimeter at 100–300 kilohertz—to disrupt cancer-cell division. Their immune effects appear to arise partly because dying tumor cells release danger signals that activate macrophages through NF-κB and MAPK pathways, although direct in vivo evidence for macrophage reprogramming remains limited. Piezoelectric materials could provide a wireless alternative: ultrasound mechanically deforms a material such as β-phase polyvinylidene fluoride, generating a local electric potential. That signal can open voltage-gated calcium channels and activate a calcium–CAMK2A–NF-κB axis, while some piezoelectric materials also catalyze reactive oxygen species.

Magnetic approaches offer deep penetration without requiring an external beam to pass through the entire tumor. Magnetic nanoparticles can convert an alternating magnetic field into localized heat, a process known as magnetic hyperthermia. Mild heating between about 39 and 45°C may release danger signals from tumor cells while also improving the inflammatory environment. At the same time, acidic tumor conditions or lysosomal processing can release iron ions from particles. Through Fenton and Fenton-like reactions, iron catalyzes the formation of highly reactive hydroxyl radicals, which can damage cancer cells and act as redox signals that favor M1-like macrophage programs. Some particles may influence macrophages without meaningful heating by disturbing iron homeostasis directly, although those effects depend strongly on size, shape, surface chemistry and intracellular dissolution. Radiation adds a clinically established but dose-sensitive option. Moderate doses of roughly 2–10 gray can increase inflammatory macrophage markers through HMGB1, ROS, ATM kinase and NF-κB signaling. Higher doses may worsen hypoxia and activate the HIF-1α–SDF-1–CXCR4 pathway, drawing in immunosuppressive macrophages instead. Ultra-high-dose-rate FLASH radiation has shown a more favorable M1/M2 balance in preclinical work, but the optimal dose, fractionation and treatment sequence remain unresolved.

The review’s central message is not that one form of energy is destined to replace immunotherapy, but that physical stimulation could make immune treatments more precise and more effective. Each modality has a different clinical niche: light is naturally suited to superficial or endoluminal lesions; focused ultrasound can reach deep targets; electrical fields are attractive where electrodes or transducer arrays can be positioned; magnetic systems can act remotely but generally require reliable nanoparticle deposition; and radiotherapy already has established planning and delivery infrastructure. The field is still dominated by laboratory and animal studies, and macrophage polarization is highly dependent on tissue context and stimulation parameters. A treatment that promotes inflammation in one tumor could produce tolerance or immunosuppression in another if the dose, timing, oxygen level or metabolic state is different. Future progress will require standardized energy dosimetry, imaging-guided delivery, spatial and single-cell immune profiling, and careful monitoring of normal-tissue injury. If those hurdles can be overcome, externally controlled energy may offer a powerful way to turn the tumor’s most adaptable immune residents against the cancer they have been helping to protect.

Glioblastoma is notorious for its resilience against conventional treatments like surgery, radiotherapy, and chemotherapy, with median survival rates seldom exceeding a year post-diagnosis. A formidable challenge in treatment stems from the tumor’s ability to exploit the body’s own biological systems to shield itself from therapeutic assault. The University of Reading’s innovative research targets this cunning defense mechanism by employing secretomes—protein-rich secretions from neural crest-derived stem cells—that effectively disrupt the cancer’s protective signaling pathways. This strategy goes beyond merely attacking the tumor cells; it reprograms the tumor microenvironment and immune response, tipping the balance against tumor survival.

In vitro assays utilizing human glioblastoma cells introduced into murine brain tissue revealed that the stem cell secretomes act on multiple fronts: they reduce tumor proliferation rates, lower the invasive capacity of cancer cells that typically enables metastatic spread within the brain, and shrink tumor masses. When combined with temozolomide—the frontline chemotherapeutic agent in glioblastoma therapy—the secretomes amplified the drug’s antitumor activity without inflicting damage on surrounding healthy brain cells. This synergy suggests an enhanced therapeutic window that could improve clinical outcomes and minimize adverse effects.

At the molecular level, the secreted proteins appear to target and neutralize specific signaling cascades that glioblastoma cells employ to manipulate host immune defenses and foster a pro-tumorigenic inflammatory milieu. Professor Darius Widera, the study’s lead investigator, explains that glioblastoma cells send immunomodulatory signals which enlist systemic immune tolerance, effectively “disarming” the patient’s natural anti-tumor immunity. The stem cell proteins disrupt these signals and simultaneously activate complementary pathways that promote inflammation hostile to the tumor, thus “flipping” the cancer’s own defensive mechanisms against itself. This dual-pathway inflammatory rebalancing represents a novel therapeutic paradigm in neuro-oncology.

Further emphasizing the clinical significance, co-author Dr. Graeme Cottrell highlights that this approach not only disarms tumor defenses but also potentiates chemotherapy’s effectiveness. Given glioblastoma’s notorious resistance to treatment, such a dual-pronged approach—disruptive immunomodulation coupled with enhanced cytotoxicity—may finally offer a breakthrough in an otherwise bleak therapeutic landscape. The researchers stress that this synergy could shift current treatment paradigms by integrating biologically derived agents alongside standard chemotherapeutics.

Technologically, the use of neural crest-derived oral mucosal stem cells presents practical advantages. These cells secrete bioactive proteins and extracellular vesicles that can be isolated, produced, and stored without reliance on live stem cell cultures. This stability allows for scalable and consistent manufacturing, addressing a critical hurdle in translating stem cell therapies to widespread clinical application. Mass production of secretomes and vesicles could lead to off-the-shelf biologics tailored to overcome glioblastoma’s complex defense strategies.

Preclinical models remain essential to evaluate safety and efficacy before clinical trials. This study employed an innovative ex vivo system, transplanting human glioblastoma cells into murine brain tissue rather than whole-animal tumor models. This technique offers a realistic brain microenvironment to assess tumor dynamics and therapeutic impact while reducing animal usage and aligning with ethical research practices focused on replacement, reduction, and refinement. Utilizing brain slice culture allows for high-resolution analysis of tumor-cell interaction and treatment response in an anatomically relevant context.

Glioblastoma affects approximately 3,200 individuals annually in the UK alone, with dismal five-year survival rates—only about 5% achieve long-term remission. Despite aggressive multimodal treatment, tumor recurrence is almost inevitable due to residual resistant cancer stem cells and immune evasion mechanisms. Novel treatments capable of perturbing the tumor-host crosstalk hold promise for extending survival and improving quality of life. The stem cell secretome approach offers insight into harnessing endogenous cell communication pathways to counteract malignancy.

Crucially, the research elucidates a deeper understanding of glioblastoma’s immunological microenvironment. Unlike many cancers, glioblastoma co-opts inflammatory signaling to create a tumor-supportive niche, subverting immune surveillance. The study’s findings indicate that targeted modulation of inflammatory rebalancing—attenuating tumor-promoting signals while inducing anti-tumor immunity—can destabilize the tumor’s microenvironment, rendering it more susceptible to eradication. This immune-centric focus could pioneer new classes of brain cancer therapies beyond cytotoxic agents.

While this research marks a significant advance, challenges remain before translation to clinical application. Further validation in more complex in vivo models and dose-optimization studies are necessary to confirm safety and efficacy on a whole-organism level. Additionally, investigations into potential immunogenic side effects and long-term stability of secretome components will inform clinical trial design. Nevertheless, the scalable production potential and the non-reliance on live cells present a compelling case for rapid development.

In summary, the stem cell-derived secretomes from oral mucosal neural crest cells represent a promising avenue to undermine glioblastoma’s formidable defenses. By directly interfering with the tumor’s protective signaling while enhancing existing chemotherapy, this strategy introduces a novel class of biologics capable of shifting the balance in favor of the patient’s immune system. As glioblastoma survival rates have remained stagnant for decades, such innovative approaches leveraging the body’s own regenerative biology might finally herald a turning point in brain cancer treatment.

Looking forward, the research team envisions moving toward advanced models that better mimic the human patient condition, ultimately progressing to clinical trials. If successful, this approach could revolutionize not only glioblastoma therapy but also broaden to other malignancies where tumor immune evasion is a major obstacle. The prospect of manipulating stem cell secretomes to reprogram tumor microenvironments may unlock new frontiers in oncology, demonstrating the transformative power of regenerative medicine and immunotherapy synergy.

Subject of Research: Animals

Article Title: Neural Crest-Derived Stem Cell Secretomes and Extracellular Vesicles Disrupt Glioblastoma through Dual-Pathway Inflammatory Rebalancing

News Publication Date: 28-Apr-2026

Web References:

• https://doi.org/10.1007/s12015-026-11133-5
• https://braintumourresearch.org/pages/glioblastoma-awareness-week

References:
University of Reading study published in Stem Cell Reviews and Reports, 28 April 2026.

Keywords: Brain cancer, glioblastoma, neural crest-derived stem cells, secretomes, extracellular vesicles, chemotherapy enhancement, tumor microenvironment, immunomodulation, inflammatory rebalancing, regenerative medicine, oncology, stem cell therapy

The core of this pioneering strategy lies in the design of IR-mRNAs encoding two key proteins: NF-κB-inducing kinase (NIK) and interferon regulatory factor 8 (IRF8). Both NIK and IRF8 are central regulators of immune cell activation and differentiation. By introducing these factors directly into the immune cells residing within tumors, the authors effectively reignite the antitumor immune machinery. Upon delivery through LNPs, these IR-mRNAs selectively activate conventional type 1 dendritic cells (cDC1s), a specialized subset of APCs known for their robust ability to prime cytotoxic CD8⁺ T cells against tumor antigens. This activation leads to a substantial increase in the population of these critical immune sentinels within the tumor microenvironment.

Further amplifying the antitumor immune response, the IR-mRNAs provoke the production of pro-inflammatory cytokines, molecules essential for robust immune activation. These cytokines create a cascade effect, recruiting and stimulating additional immune effector cells to infiltrate the tumor. The net result is a profound remodeling of the tumor microenvironment from an immunologically “cold” state—characterized by immune suppression and evasion—to a “hot” state marked by active immune surveillance and attack. This shift is crucial for overcoming one of the greatest obstacles in cancer therapy: the immune system’s inability to recognize and effectively attack malignant cells within their protective niches.

What makes this approach especially compelling is its versatility in terms of administration routes. The researchers demonstrated that LNP-encapsulated IR-mRNAs could elicit durable antitumor responses not only when delivered intratumorally but also systemically through intravenous injection. This flexibility broadens the therapeutic potential, allowing for application in various clinical settings and tumor types. The effectiveness was confirmed across multiple syngeneic mouse tumor models, a key step in validating the generalizability and robustness of the strategy.

Adding another layer of sophistication to their approach, the investigators explored the synergistic effects of coadministering IR-mRNAs alongside mRNA vaccines encoding tumor antigens. When ovalbumin mRNA was delivered in tandem with IR-mRNAs, the antigen-specific CD8⁺ T cell response was amplified roughly tenfold. This dramatic enhancement not only improved immediate tumor control but also established sustained long-term immunological memory, effectively preventing tumor growth in vaccinated mice. Such durable immunity is the holy grail of cancer immunotherapy, potentially providing lifelong protection against tumor recurrence.

The concept of combining IR-mRNAs with antigen-encoding mRNAs was extended beyond model antigens to clinically relevant targets. Specifically, coadministration with hemagglutinin mRNA, which encodes a well-known viral antigen used as a model for immunization studies, yielded remarkable enhancements in both humoral and cellular immune responses. Antibody production increased by approximately five times, while cellular responses were amplified about fifteenfold. This underscores the potential application of IR-mRNAs as potent adjuvants capable of boosting adaptive immunity across diverse vaccine platforms.

From a mechanistic standpoint, the IR-mRNAs appear to act as potent immunomodulators that reprogram resident immune cells toward an activated phenotype. NIK, through its role in NF-κB signaling, orchestrates the transcriptional upregulation of numerous genes critical for immune function, including costimulatory molecules and cytokines. IRF8, on the other hand, is pivotal for the development and functional maturation of dendritic cells, particularly those involved in cross-presentation—a key process for eliciting cytotoxic T cell responses against tumors. The combined expression of these factors inside the tumor microenvironment sets off a multifaceted immune activation that has proven difficult to achieve with conventional therapies.

This research also signals a paradigm shift in the design of cancer immunotherapies, moving away from systemic immune checkpoint blockade alone towards localized immune modulation complemented by systemic delivery strategies. By harnessing the power of mRNA technology and nanoparticle delivery systems, the study bridges the gap between precision molecular engineering and clinical translational potential. The use of lipid nanoparticles, already clinically validated through mRNA vaccines against infectious diseases, lends further feasibility and safety to this approach.

The profound antitumor efficacy observed in preclinical models offers a promising preview of clinical applicability. The durable responses induced across various tumor types suggest that this approach could overcome tumor heterogeneity and immune evasion mechanisms that have traditionally limited immunotherapy success. Furthermore, the ability to induce robust immune memory has significant implications for long-term patient outcomes, potentially reducing relapse rates and improving survival.

Looking ahead, the adaptability of this technology to encode other immunostimulatory factors or tumor antigens could open new avenues for personalized cancer vaccines and combination immunotherapies. By tailoring the mRNA payloads to individual patient tumor profiles, the approach might achieve unprecedented specificity and potency. Additionally, integration with existing therapies such as checkpoint inhibitors or adoptive cell transfer could synergistically amplify therapeutic benefits.

In conclusion, these findings represent a milestone in cancer immunotherapy, demonstrating that targeted delivery of IR-mRNAs encoding NIK or IRF8 within tumors can robustly remodel the immune landscape, generating potent and durable antitumor immunity. This innovative strategy offers a new toolkit for overcoming the immunosuppressive tumor microenvironment and enhancing both cellular and humoral immune responses. As the field moves toward clinical translation, this work lays the foundation for next-generation immunotherapies with the potential to transform cancer treatment paradigms and improve patient outcomes worldwide.

Subject of Research: Immune modulation in the tumor microenvironment using engineered messenger RNAs delivered via lipid nanoparticles to enhance antitumor immunity.

Article Title: Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models.

Article References:
Gupta, A., Das, R., Reed, K. et al. Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models. Nat Biotechnol (2026). https://doi.org/10.1038/s41587-026-03115-2

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41587-026-03115-2

One particularly promising modality emerging in recent years is sonodynamic therapy (SDT), which exploits ultrasound waves to activate sonosensitizers preferentially accumulated within tumors. SDT offers superior deep tissue penetration and precise spatiotemporal control compared to traditional photodynamic therapy. However, existing sonosensitizers face substantial limitations. Inorganic-based systems often suffer from poor biodegradability and potential long-term toxicity. Meanwhile, purely organic small molecule sensitizers lack the versatility needed for multifunctional integration and efficient reactive oxygen species (ROS) generation. To surmount these obstacles, Ming Wu and colleagues at the Gongli Hospital of Pudong New Area have pioneered an innovative sonodynamic platform based on covalent organic frameworks (COFs), which are crystalline, porous polymers known for their tunable structures, biocompatibility, and abundant functionalization sites.

Their groundbreaking study reports the synthesis of ferrocene-modified nanoscale COFs (mCOFs) that marry the structural advantages of COFs with the catalytic properties of ferrocene moieties. By reacting microscale COFs with aminoferrocene, the researchers achieved effective nanosizing alongside the integration of Fenton-like catalytic centers. This dual functionality is pivotal: under ultrasonic irradiation, mCOFs generate singlet oxygen (^1O_2), a potent cytotoxic ROS, while the embedded ferrocene units catalyze the conversion of the naturally elevated hydrogen peroxide (H_2O_2) within the tumor microenvironment into highly reactive hydroxyl radicals (·OH). This tandem ROS amplification enables enhanced oxidative stress, resulting in robust tumor cell lethality.

Comprehensive physicochemical characterization confirmed that the mCOFs exhibit optimal particle size, dispersibility in biological media, and crystalline integrity—a foundation critical for reproducible biological activity. Additionally, in vitro assays demonstrated that mCOFs efficiently enter 4T1 breast cancer cells and induce markedly increased intracellular ROS upon ultrasound exposure. These ROS bursts trigger different cell death pathways, including apoptosis and ferroptosis, as evidenced by elevated lipid peroxidation and mitochondrial dysfunction markers. Unlike apoptosis, which is caspase-dependent programmed cell death, ferroptosis is characterized by iron-dependent lipid peroxidation, providing mechanistic synergy through complementary cytotoxic mechanisms.

Beyond direct tumoricidal effects, the mCOF + ultrasound combination stimulated immunogenic cell death (ICD)—a form of apoptosis that heightens anti-tumor immune responses. The hallmark features of ICD, such as the release of damage-associated molecular patterns (DAMPs) like ATP, were significantly upregulated. This, in turn, promoted the maturation and activation of dendritic cells (DCs), critical antigen-presenting cells in orchestrating adaptive immunity. Pro-inflammatory cytokines including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) were also elevated, fostering an inflamed microenvironment conducive to immune-mediated tumor clearance.

Moving from cell culture to animal models, the team employed orthotopic breast tumor-bearing mice to evaluate therapeutic efficacy and biodistribution. Intravenous administration of mCOFs achieved high tumor accumulation due to favorable nanoscale dimensions and surface properties, with sonodynamic activation significantly suppressing tumor growth without obvious systemic toxicity. Furthermore, in a clinically relevant bone metastasis model, mCOF treatment attenuated osteolytic lesions, preserving bone volume fraction and mineral density. These results underscore the ability of mCOFs not only to control primary tumors but also to mitigate metastatic spread and bone destruction, which are principal causes of morbidity and mortality.

Immunophenotyping of tumor-infiltrating leukocytes revealed striking increases in mature DCs, helper CD4+ T cells, cytotoxic CD8+ T cells, natural killer (NK) cells, and interferon-gamma (IFN-γ)-producing CD8+ T cells after mCOF + ultrasound treatment. This immune remodeling indicates that the sonodynamic platform effectively reverses tumor immunosuppression and mobilizes both innate and adaptive immune arms to mount a concerted attack against cancer. Such remodeling is critical for durable responses and prevention of metastatic recurrence.

The innovation in this study lies in the precise integration of sonodynamic therapy with Fenton reaction-based chemotherapy and immune modulation via a single nanoscale platform. The ferrocene modification imparts catalytic ROS amplification, overcoming the intrinsic oxidative resistance of tumors, while the COF scaffold ensures structural robustness and biocompatibility. By eliciting ICD alongside ferroptosis and apoptosis, the mCOFs stimulate systemic antitumor immunity—a distinct advantage over conventional therapies that often induce immunologically silent cell death facilitating tumor escape.

This research sets a precedent for the rational design of multifunctional sonosensitizers employing covalent organic frameworks as versatile carriers. The top-down approach to ferrocene incorporation opens avenues for tailoring nanoformulations with synergistic therapeutic mechanisms. Importantly, the successful suppression of both breast cancer progression and its devastating bone metastases highlights the clinical translational potential of mCOFs. Such innovations are urgently needed to address unmet needs in metastatic breast cancer treatment paradigms.

Ming Wu and collaborators emphasize that their findings also reinforce the concept that combining sonodynamic therapy with immunomodulation may overcome the historical limitations of therapies focused solely on primary tumor ablation. This multidimensional strategy disrupts the permissive tumor microenvironment favoring metastasis and immune evasion.

In conclusion, the ferrocene-modified nanoscale covalent organic framework platform represents a leap forward in cancer nanomedicine. It harnesses ultrasound-triggered ROS generation augmented by Fenton catalysis, induces dual apoptosis and ferroptosis pathways, and recalibrates the tumor immune milieu to achieve comprehensive tumor control. Future investigation into clinical translation, pharmacokinetics, and combinatorial regimens with immunotherapy could further enhance its therapeutic impact, potentially revolutionizing the management of metastatic breast cancer and other solid tumors.

Subject of Research: Ferrocene-Modified Nanoscale Covalent Organic Frameworks for Multifunctional Sonodynamic Therapy in Breast Cancer and Bone Metastasis

Article Title: Ferrocene-Modified Nanoscale Covalent Organic Frameworks for Ferroptosis-Based Sonodynamic Therapy Inhibit Breast Cancer and Its Bone Metastasis

News Publication Date: March 23, 2026

References: Published in Cyborg and Bionic Systems

Image Credits: Ming Wu, Gongli Hospital of Pudong New Area

Keywords: Breast cancer, bone metastasis, sonodynamic therapy, covalent organic frameworks, ferrocene, reactive oxygen species, ferroptosis, immunogenic cell death, tumor microenvironment, nanomedicine, oxidative stress, immune modulation

RB-1355 is distinguished by its unique mechanism of action which centers on the use of a patient’s own macrophages, a type of immune cell often residing in the tumor milieu. These macrophages are extracted and then subjected to an ex vivo hyperactivation process using proprietary methodologies designed to induce a robust pro-inflammatory and immune-supportive phenotype. This reprogramming effectively converts macrophages from potentially tumor-promoting actors to powerful anti-tumor effectors. Upon reintroduction into the patient’s lesions via direct intratumoral injections, these engineered macrophages reshape the tumor microenvironment by igniting a cascade of immune responses that encompass activation of neoantigen-specific T cells and B cells, thereby orchestrating a comprehensive immune assault on lymphoma cells.

One of the most compelling advantages of RB-1355 therapy is the rapid manufacturing pipeline, which allows for treatment readiness in approximately one week. This expedited timeline stands in stark contrast to other cell therapies which often require extended preparation periods, thereby making RB-1355 a more accessible option that can be deployed in a timely manner. Additionally, the therapy circumvents the need for lymphodepleting chemotherapy, a common preconditioning regimen that can cause considerable toxicity. This attribute not only enhances safety but also broadens the eligibility of patients who can receive the therapy irrespective of tumor mutational status, positioning RB-1355 as a versatile therapeutic across a spectrum of B-cell and T-cell lymphomas.

The initial clinical findings have been presented at the prestigious 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR), showcasing promising efficacy signals. Among thirteen heavily pretreated patients enrolled in the trial, two individuals with diffuse large B-cell lymphoma (DLBCL) achieved complete remission, notably including those who had previously failed CAR T cell therapy—a population with extremely limited treatment options. These responses, including durability beyond 100 days for one patient, underscore the potential of RB-1355 to address aggressive, refractory disease in a clinical setting.

In addition to complete remissions, partial responses were also observed in patients suffering from peripheral T-cell lymphoma and mycosis fungoides, malignancies traditionally resistant to standard therapies. This breadth of activity exemplifies RB-1355’s capacity to generate meaningful clinical benefit across heterogeneous lymphoma subtypes. Equally important is the favorable safety profile reported from the trial; no dose-limiting toxicities were encountered, and only three instances of low-grade adverse effects were noted, indicating that RB-1355 is not only efficacious but also well tolerated in a fragile patient population with limited alternatives.

From an immunological standpoint, the macrophage-centric approach of RB-1355 leverages the plasticity of these myeloid cells to break the immune tolerance often established in the tumor microenvironment. By instigating an inflammatory cascade, it promotes antigen presentation and stimulates both innate and adaptive immune components. This dual activation is critical for achieving sustained anti-lymphoma activity, given the complex immune evasion strategies employed by malignant lymphocytes. Furthermore, this method does not depend on the presence of specific actionable mutations in the lymphoma cells, enabling a broad-spectrum therapeutic effect that could redefine treatment algorithms for refractory lymphomas.

The potential implications for patients are profound. Historically, relapsed and refractory non-Hodgkin lymphoma cases have represented a therapeutic dead-end with limited durable options. RB-1355’s promising early results suggest it could fill this unmet need by offering a new avenue for disease control, especially for those who have exhausted conventional chemotherapy, targeted agents, and even advanced therapies like CAR T cells. The rapid preparation and administration of RB-1355 could also minimize delays in treatment initiation, a critical factor in managing aggressive lymphomas.

Current ongoing investigations aim to optimize RB-1355 through dose escalation and repeated treatment cycles to enhance the durability of responses and potentially increase remission rates. Researchers are also exploring synergistic combinations with other immunomodulatory agents to further amplify anti-lymphoma immunity. As the body of evidence grows, RB-1355 may represent the next frontier in cell therapy by expanding the types of immune cells engineered and by circumventing the limitations associated with existing therapies that primarily target T cells.

Moreover, the development of RB-1355 reflects a growing appreciation in oncology of the tumor microenvironment’s role in cancer progression and response to therapy. Unlike approaches that solely target malignant cells, therapies like RB-1355 aim to re-educate the immune ecosystem surrounding the tumor, creating an inhospitable environment for cancer cell survival. Such strategies could herald a new class of treatments for hematologic malignancies and potentially solid tumors, enabling a more holistic immune-based eradication of cancer.

The involvement of BobcatBio in supporting this research illustrates the critical importance of collaboration between academic institutions and biotechnology enterprises in translating cutting-edge science into clinical realities. The rapid translation from bench to bedside exemplifies how innovations in cellular manufacturing and immune engineering can swiftly impact patient care in fields where therapeutic needs remain urgent.

In conclusion, RB-1355 represents an innovative and promising cell therapy that reshapes the landscape of non-Hodgkin lymphoma treatment by utilizing hyperactivated macrophages to generate a multi-dimensional immune response without the need for conventional preconditioning regimens. Early clinical data show encouraging safety and efficacy profiles in patients with relapsed or refractory disease, including those unresponsive to CAR T therapies. Continued clinical development will delineate its role within the expanding arsenal against aggressive lymphomas, potentially offering hope to a patient population with critical unmet needs.

Subject of Research: Novel cell therapy RB-1355 for relapsed and refractory non-Hodgkin lymphoma

Article Title: RB-1355: A Macrophage-Based Cell Therapy Revolutionizing Treatment of Refractory Non-Hodgkin Lymphomas

News Publication Date: 2026 (Date of presentation at ASTCT/CIBMTR 2026 Tandem Meetings)

Web References:

• MD Anderson Non-Hodgkin Lymphoma Overview: https://www.mdanderson.org/cancer-types/non-hodgkin-lymphoma.html
• CAR T Cell Therapy at MD Anderson: https://www.mdanderson.org/treatment-options/car-t-cell-therapy.html
• Paolo Strati, M.D. Profile: https://faculty.mdanderson.org/profiles/paolo_strati.html
• ASTCT/CIBMTR Tandem Meetings 2026 Program: https://www.tandemmeetings.com/
• Full Abstract: https://tandem.virtual-meeting.org/programme/presentation/677607

Keywords:
Cell therapies, macrophage immunotherapy, non-Hodgkin lymphoma, relapsed lymphoma, refractory lymphoma, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, mycosis fungoides, tumor microenvironment, immunotherapy, RB-1355, novel cancer treatments

Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide, largely due to its ability to evade immune surveillance. Tumors develop multiple sophisticated mechanisms to subvert the immune system’s recognition and attack processes, allowing unchecked growth and metastasis. One pivotal pathway implicated in this evasion involves PTPN13, a phosphatase that modulates signaling cascades essential for immune cell activation and tumor suppression.

The study elucidates that PTPN13 interacts directly with the APC protein, a well-known tumor suppressor whose mutation is frequently linked to colorectal carcinogenesis. The research team discovered that the C-terminal of APC harbors a specific 11-amino-acid sequence that can effectively bind and inhibit PTPN13, thereby disrupting its oncogenic signaling. This peptide, once synthesized and introduced exogenously, was shown to significantly impair the functional activity of PTPN13 in CRC models.

Employing advanced molecular biology techniques and in vivo models, the investigators demonstrated that the peptide-mediated inhibition of PTPN13 restored immune system recognition of tumor cells. More specifically, this intervention reactivated cytotoxic T lymphocytes and other immune effector cells previously suppressed by the tumor milieu. Consequently, the immune checkpoint blockade efficacy was enhanced, suggesting a synergistic potential with existing immunotherapies.

From a mechanistic perspective, PTPN13 exerts its oncogenic role by dephosphorylating key signaling proteins involved in T-cell receptor (TCR) signaling pathways. By impeding these downstream pathways, the enzyme facilitates an immunosuppressive microenvironment conducive to tumor survival. The APC-derived peptide, by antagonizing PTPN13, reinstates phosphorylation-dependent signaling necessary for robust immune responses.

Further biochemical analyses revealed that the peptide’s interaction with PTPN13 induces conformational changes impairing its phosphatase activity. Structural modeling, combined with binding affinity assays, confirmed the peptide’s high specificity and potency. Moreover, the treatment was found to have minimal off-target effects, underscoring its therapeutic viability.

Importantly, the study also addressed tumor heterogeneity and evaluated the peptide’s efficacy across various CRC subtypes. The results underscored a broad-spectrum activity, with significant tumor growth suppression observed in both microsatellite stable and instable CRC cell lines. This bodes well for overcoming the challenges posed by genetic variability among colorectal tumors.

One of the most striking implications of this research lies in its potential to overcome resistance mechanisms that commonly limit the success of checkpoint inhibitors and other immunotherapies. By directly targeting a novel immune evasion molecule, the peptide can sensitize ‘cold’ tumors—those lacking adequate immune infiltration—to immune-mediated destruction.

Looking ahead, the integration of this peptide-based approach with conventional chemotherapy or radiotherapy could revolutionize treatment paradigms for colorectal cancer. This combination strategy may not only improve response rates but also reduce adverse effects by enabling lower doses of cytotoxic agents.

The research contributes invaluable insights into the molecular crosstalk between tumor suppressors and immune regulators in the cancer microenvironment. It paves the way for the development of peptide-based therapeutics that leverage the natural tumor-suppressive functions of APC to negate immune escape tactics employed by cancer cells.

While clinical translation remains at an early stage, the study’s robust preclinical datasets provide a compelling rationale for advancing this peptide therapy into human trials. Critical future work will focus on optimizing delivery methods, pharmacokinetics, and dosing regimens to maximize therapeutic efficacy and safety profiles.

In essence, targeting PTPN13 with a precise peptide fragment derived from APC represents a novel and elegant strategy to convert an immune-silent colorectal tumor landscape into one amenable to attack by the body’s own defense system. This research not only identifies a previously unrecognized interface between tumor suppression and immune modulation but also offers new hope for patients battling colorectal cancer worldwide.

The implications of this discovery extend beyond colorectal cancer, opening avenues to explore similar peptide-based interventions in other malignancies where PTPN13 or related phosphatases contribute to immune evasion. It exemplifies the power of molecular precision in designing cancer therapies with enhanced specificity and diminished toxicity.

In conclusion, this landmark study elucidates a critical immunological vulnerability in colorectal cancer and harnesses the tumor suppressor APC’s C-terminal peptide to disrupt PTPN13-driven immune escape. By empowering immune cells and bypassing established resistance mechanisms, this approach promises to transform the clinical management of colorectal cancer, potentially improving survival outcomes and quality of life for countless patients.

Subject of Research: Colorectal cancer immunotherapy, PTPN13 inhibition, APC-derived peptides, tumor immune evasion mechanisms.

Article Title: Targeting PTPN13 with 11-amino-acid peptides of C-terminal APC prevents immune evasion of colorectal cancer.

Article References:
Ma, WH., Li, WY., Chen, T. et al. Targeting PTPN13 with 11-amino-acid peptides of C-terminal APC prevents immune evasion of colorectal cancer. Cell Res 36, 72–93 (2026). https://doi.org/10.1038/s41422-025-01206-4

Image Credits: AI Generated

DOI: January 2026

The research begins by addressing the pressing need for novel strategies in treating DLBCL, one of the most prevalent forms of non-Hodgkin lymphoma. With current treatment modalities offering limited success, especially in advanced stages, the researchers undertook the task of elucidating how tumor microenvironments can be recalibrated to enhance anti-tumor immunity. The role played by immune cells and the metabolic alterations within the tumor microenvironment is central to this ongoing quest for therapeutic efficacy.

The team employed a range of cellular and animal model systems to evaluate the impact of SH3BP5 on various immune signaling pathways. The results are striking, showing that SH3BP5 not only impacts the metabolic pathways within tumor cells but also modifies the immune cell activity in such a way that enhances tumor-killing responses. This dual effect—emanating from a single mediator—opens up fascinating avenues for combined metabolic and immune interventions in cancer therapy.

One of the striking aspects of their findings is the delineation of the mechanisms through which SH3BP5 affects immune cell functionality. By engaging key metabolic enzymes and pathways, SH3BP5 appears to create an environment conducive to sustaining immune responses against malignant cells. The breakdown of this process showed the researcher team how fine-tuning metabolic pathways could significantly enhance T-cell function while limiting the immune evasion tactics employed by tumors.

A notable component of the study reveals a shift in the balance between effector T-cells and regulatory T-cells in SH3BP5-high tumors. The interplay between these two cell types is critical, as effector T-cells are responsible for direct tumor attack, while regulatory T-cells often serve to suppress such immune responses. By skewing this balance, SH3BP5 may very well represent a promising target to elevate anti-tumor responses while mitigating the effects of immunosuppression—a hallmark of advanced cancers.

This research lays the groundwork for subsequent trials aimed at manipulating SH3BP5 activity in patients. By developing inhibitors or enhancers of SH3BP5, we can foresee a new line of treatment that not only targets the tumor cells directly but also bolsters the body’s natural immune defenses. Such strategies could be game-changers in oncology, particularly for DLBCL patients with poor prognosis.

In addition to DLBCL, the implications of SH3BP5-mediated metabolic-immune crosstalk could extend to a host of other malignancies where metabolic reprogramming plays a critical role. Given that cancer cells often exploit metabolic pathways for growth and survival, understanding how these signaling networks interface with immune responses might unveil universal therapeutic targets.

Moreover, the collaborative nature of this research underscores the importance of interdisciplinary approaches in tackling complex diseases. Combining insights from immunology, metabolism, and cancer biology, the authors emphasize how the future of oncology may rely heavily on a systems biology perspective. This paradigm shift necessitates the integration of various scientific disciplines to provide a holistic view of cancer progression and treatment.

As the study advances to the potential clinical translations, the authors call for collaborative efforts across academic institutions and pharmaceutical companies. Engaging a broad array of stakeholders including clinicians, basic science researchers, and industry partners will be essential in bringing these promising discoveries to the clinic. The journey from laboratory bench to patient bedside is fraught with challenges, but the potential for improving patient outcomes in DLBCL is a compelling motivator.

This research also places a significant emphasis on the need for biomarker-driven strategies in oncology. The identification of SH3BP5 as a prognostic factor brings to light the crucial role that precise biomarkers can play in tailoring individual treatment regimens. The future of cancer therapy may lie in our ability to harness these biomarkers to classify tumors more accurately and predict patient responses to specific therapies.

In conclusion, the study led by Wu et al. represents a significant step forward in understanding the dual role of SH3BP5 in DLBCL. By bridging metabolic and immune pathways, this research not only sheds light on the complexities of the tumor microenvironment but also opens new avenues for targeted therapy. As oncologists and researchers alike look toward the future, the potential of reshaping immunosuppressive environments through metabolic mediators like SH3BP5 stands as a hopeful beacon in the fight against cancer.

This ongoing exploration into SH3BP5’s contribution to metabolic-immune interactions is poised to inspire further research, leading to innovative therapies that can potentially transform clinical outcomes for patients afflicted by DLBCL and other malignancies with similar immune evasion characteristics. As data continues to emerge, we can only anticipate the profound implications that these findings will have in the development of future cancer treatments, ultimately providing a lifeline to those battling this challenging disease.

Subject of Research: SH3BP5-driven metabolic-immune crosstalk in DLBCL

Article Title: SH3BP5-driven metabolic-immune crosstalk in DLBCL: a prognostic biomarker and therapeutic target for reshaping immunosuppressive microenvironment.

Article References:
Wu, T., Yang, Y., Zong, Y. et al. SH3BP5-driven metabolic-immune crosstalk in DLBCL: a prognostic biomarker and therapeutic target for reshaping immunosuppressive microenvironment. J Transl Med 23, 1003 (2025). https://doi.org/10.1186/s12967-025-06951-z

Image Credits: AI Generated

DOI:

Keywords: DLBCL, SH3BP5, metabolic pathways, immune responses, prognostic biomarker, therapeutic target, cancer therapy.

Glioblastoma’s resistance to current therapies has long been attributed in large part to its immunosuppressive microenvironment, which severely limits the infiltration, survival, and function of therapeutic T cells. Traditional CAR T cell therapies that have demonstrated remarkable success against hematological malignancies face formidable obstacles when targeting solid tumors like glioblastoma. The lack of sustained T cell activation and the prevalence of exhaustion phenotypes contribute to their diminished efficacy. Addressing this formidable challenge, the research team exploited a gene therapy approach that genetically engineers hematopoietic progenitor cells to produce monocytes and macrophages capable of selectively releasing immunostimulatory cytokines upon tumor infiltration.

This precision delivery system utilizes a dual-cytokine strategy within the TME. Interferon-alpha (IFN-α), known for its multifaceted immune-enhancing properties, counters immunosuppressive cues, improves antigen presentation, and amplifies the activity of immune effector cells. Concurrently, an engineered mutation of interleukin-2 (IL-2) selectively activates a mutated receptor expressed exclusively on the administered CAR T cells, ensuring that only these therapeutic cells receive proliferative signals without triggering systemic toxicities. The co-expression of this mutant IL-2 receptor and the mutant cytokine creates a private, tumor-confined signaling axis that fine-tunes the immune response.

The study employed murine models that faithfully recapitulate human glioblastoma pathophysiology and immunological barriers, enabling comprehensive evaluation of the therapeutic paradigm. In these models, CAR T cells administered alone demonstrated minimal antitumor effects, mirroring clinical trial outcomes where CAR T cells have struggled to control solid tumors. However, when combined with tumor-targeted cytokine delivery, the CAR T cells exhibited restored functional potency, resulting in pronounced delays in tumor growth and significant improvements in survival. Notably, the antitumor response extended even to tumors with heterogeneous antigen expression, suggesting that the approach transcends single antigen targeting by enlisting endogenous T cells through a mechanism known as antigenic spreading.

Antigenic spreading is a critical immune phenomenon whereby an initial immune response against a specific tumor antigen broadens to include additional tumor-associated antigens. This results in a more robust and comprehensive antitumor immunity capable of counteracting tumor immune evasion strategies. The researchers found that IFN-α played a pivotal role in orchestrating this process by reshaping the TME into an immune-stimulatory milieu that recruits and activates the host’s own T cell populations alongside the engineered CAR T cells. This cooperative engagement of multiple immune cell subsets provides a promising foundation for durable tumor control.

Central to the approach is the reprogramming of tumor-associated macrophages, which are ordinarily contributors to the immunosuppressive environment. By incorporating genes encoding the cytokines under tight regulatory control into hematopoietic progenitors, the resulting macrophages deliver the immunostimulatory payload directly within the tumor niche. This localized cytokine release modifies the TME and facilitates a conducive environment for CAR T cell persistence and activation. The spatial precision of this cytokine delivery minimizes systemic exposure, thereby reducing the risk of adverse effects that have hampered previous systemic cytokine therapies.

The concept of private cytokine cross-talk established in this study represents a paradigm shift in immunotherapy. Rather than systemic administration of immune stimulants—which often result in dose-limiting toxicities and off-target effects—this method confines cytokine activity to the precise cellular players and anatomical location implicated in antitumor immunity. According to co-first author Dr. Alvisi, this targeted interaction “ensures that immune stimulants act only where needed, sparing the rest of the body from systemic toxicity, and specifically on the relevant target cells involved in tumor attack.”

This research also builds on the prior success of the gene therapy platform now implemented in a first-in-human clinical trial, the Temferon trial (NCT03866109), conducted by Genenta Science, a biotech spin-off originating from the San Raffaele Institute. Temferon leverages the selective delivery of IFN-α to glioblastoma lesions as a stand-alone treatment, demonstrating feasibility, safety, and preliminary biological activity in human subjects. While early results highlight promising modulation of the tumor microenvironment and hints of therapeutic benefit, the intrinsic limitations of a phase 1 study with a small patient cohort warrant further exploration into combination strategies.

The present study’s demonstration that coupling the Temferon approach with CAR T cell therapy potentiates antitumor efficacy opens exciting avenues for clinical translation. By broadening the therapeutic arsenal against glioblastoma, this combinatory strategy could overcome the historical resistance encountered by cellular immunotherapies targeting solid tumors. The robust engagement of endogenous T cells and the generation of a more permissive microenvironment underscore the potential to combat tumor heterogeneity and immune escape alike.

The implications of this work extend beyond glioblastoma, providing a blueprint for integrating gene therapy-driven macrophage reprogramming with engineered T cell therapies across diverse solid tumor indications. It exemplifies a sophisticated interplay between cellular therapies and localized gene delivery systems to coax the immune system into mounting a potent and selective antitumor response. Such convergence of technologies might redefine therapeutic paradigms in oncology, pushing the boundaries of what is achievable with precision immunotherapy.

Luigi Naldini, Director of SR-TIGET, remarks, “This work represents another important step forward in our decade-long commitment to develop novel gene and cell therapy strategies effective against tumors… A combination of Temferon with CAR T cell administration, as prompted by our new study, could in future further enhance the benefit of the treatment and broaden its efficacy.” This sentiment captures the transformative potential of bridging innovative genetic engineering with advanced cellular therapies to tackle one of the most challenging malignancies known to medicine.

In conclusion, the study presented by the SR-TIGET team delivers a compelling demonstration of how tumor-targeted cytokine delivery can rescue CAR T cell function and orchestrate a coordinated antitumor immune response in glioblastoma. By constructing a private cytokine communication channel within the tumor, the therapy not only revitalizes CAR T cells but also mobilizes broad host immunity, marking a significant stride toward effective immunotherapeutics in solid cancers. The journey from genetic engineering of progenitors to clinical translation exemplifies the power of integrative science to innovate in the fight against cancer, inspiring hope for patients and clinicians alike facing the daunting prognosis of glioblastoma.

Subject of Research: Immunotherapy, Gene Therapy, Glioblastoma, CAR T Cells, Tumor Microenvironment, Cytokine Delivery

Article Title: A cross-talk established by tumor-targeted cytokines rescues CAR T cell activity and engages host T cells against glioblastoma in mice

News Publication Date: 2-Jul-2025

Web References:

• DOI: 10.1126/scitranslmed.ado9511
• Temferon Trial: NCT03866109
• San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET): https://research.hsr.it/en/institutes/san-raffaele-telethon-institute-for-gene-therapy.html
• Genenta Science: https://www.genenta.com/

Image Credits: San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET)

Keywords: Glioblastoma, CAR T Cells, Gene Therapy, Cytokines, Tumor Microenvironment, IFN-α, Interleukin-2, Macrophage Reprogramming, Immune Cross-talk, Antigenic Spreading, Temferon, Solid Tumor Immunotherapy